Alon Lazarus bought HOWL once, on May 4, 2021

Lazarus Alon, Ph.D. was a biotechnology investor and board director who served as a Director and 10% owner of both Werewolf Therapeutics, Inc. (NASDAQ: HOWL) and Keros Therapeutics, Inc. (NASDAQ: KROS).( At Werewolf Therapeutics he was a member of the Board of Directors and a significant shareholder, holding more than 10% of the company’s stock and participating in equity awards and option grants disclosed in SEC Form 4 filings.( He likewise held a substantial stake in Keros Therapeutics, owning approximately 2,036,140 shares—an interest valued at around $24 million as of March 2025—and was disclosed as a director and 10 percent owner of that company.( His insider trading activity over several years primarily reflected long-term, strategic positions in these development‑stage biopharmaceutical companies rather than frequent trading.(

Dr. Lazarus’s professional profile placed him at the intersection of biotech investing and corporate governance, where he contributed to the oversight of clinical‑stage therapeutic portfolios at both Werewolf and Keros.( He served on Werewolf Therapeutics’ Board of Directors, including its audit committee, until his death on September 30, 2025, an event the company reported as a material development because it temporarily left the audit committee out of compliance with Nasdaq’s minimum size requirements.( Public filings list his mailing address in Lexington, Massachusetts, suggesting a U.S. base for his investment and board activities.( Beyond his roles as director and major shareholder and the reference to him as “Dr.” and “Ph.D.” in company disclosures, no additional verified details about his earlier career or academic background are available in public securities or market filings.(

Written by Perplexity from public sources.